Introduction: This program of research investigated the acute effects of orally ingested (Study 1) and vaporised (Study 2) cannabis containing delta-9-tetrahydrocannabinol (THC) on cognitive functions relevant for driving in two samples of medicinal cannabis patients (Study 1 N = 41 oral users; Study 2 N = 37 flower users).
Method: Participants completed counterbalanced baseline (no cannabis) and cannabis consumption (post-cannabis) appointments scheduled approximately 1 week apart. During each session, participants were administered a cognitive battery assessing information processing speed, sustained and divided attention, inhibitory control and mental flexibility. In the post-cannabis condition, the battery was completed 90 min after consuming one dose of cannabis oil (Study 1) or 15 min after vaporising one dose of cannabis flower (Study 2).
Results: In both samples, acute cannabis oil and flower administration did not induce a change in information processing speed, divided and sustained attention, or inhibitory control performance (after excluding participants with a positive drug indication at the start of either session), highlighting the moderating role of tolerance. However, significant reductions in TMT B performance were observed. Further, TMT ratio was significantly reduced post consumption of cannabis oil.
Discussion and conclusions: TMT B may be sensitive to acute cannabis consumption in medicinal cannabis patients. However, further research is needed to determine the nature and duration of these effects, and whether such effects vary depending on the population studied (e.g., regular vs. new users).
Keywords: THC; cannabis; cognition; delta‐9‐tetrahydrocannabinol; neuropsychology.
© 2025 The Author(s). Drug and Alcohol Review published by John Wiley & Sons Australia, Ltd on behalf of Australasian Professional Society on Alcohol and other Drugs.